Frontotemporal dementia (FTD) is the second most common form of dementia in people aged under 65 years, and encompasses two main clinical manifestations: behavioural changes with executive dysfunction, so-called behavioural-variant FTD (bvFTD), or predominant language impairment, so-called primary progressive aphasia (PPA) 1,2 (BOX 1). PPA can be further divided into semantic variant PPA (svPPA), non fluent variant PPA (nfvPPA) and logopenic variant PPA (lvPPA) 2 . Patients can develop concomitant parkinsonism or motor neuron disease (MND) at an early or late stage in the disease course, which results in a broad clinical phenotype that ranges from amyotrophic lateral sclerosis (ALS) to progressive supranuclear palsy (PSP) and corticobasal syndrome 3 (FIG. 1) . Patients who present with nfvPPA can develop characteristic features of PSP or corticobasal syndrome over time, whereas lvPPA is frequently associated with underlying Alzheimer disease (AD).
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Postmortem examination of the brains of people who present clinically with FTD reveals frontotemporal lobar degeneration (FTLD) associated with inclusions of either microtubule-associated protein tau (referred to as FTLD-tau), TAR DNA-binding protein 43 (TDP-43; referred to as FTLD-TDP), or RNA-binding protein fused in sarcoma (referred to as FTLD-FUS) 3 . Rare cases of FTLD are characterized by ubiquitin-positive inclusions without immunoreactivity for TDP-43 or FUS (referred to as FTLD-UPS). Correlation between the clinical presentation and specific underlying pathology is poor in bvFTD compared with svPPA and FTD associated with MND, both of which are associated with TDP-43 pathology 4 . Postmortem examination of patients who developed symptoms consistent with PSP or corticobasal syndrome often reveals FTLD-tau. In contrast to sporadic FTD, the underlying pathology in genetic FTD can be accurately predicted (FIG. 1) .
FTD is highly heritable, and 10-20% of all cases are caused by mutations in three genes: MAPT (encoding microtubule-associated protein tau), GRN (encoding progranulin, also known as acrogranin), and C9orf72 (encoding protein C9orf72) 3 . Other rare FTLD-associated genes include CHMP2B (encoding charged multivesicular body protein 2B), VCP (encoding valosin containing protein), SQSTM1 (encoding sequestosome-1), TARDP (encoding TDP-43), and TBK1 (encoding the serine-threonine-protein kinase TBK1) -the latter being the most recently discovered
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Frontotemporal lobar degeneration
The pathological term for a group of neurodegenerative disorders affecting the frontal and/or temporal lobes accompanied by protein inclusions (such as tau, TDP-43 or FUS).
Diffusion tensor imaging
An MRI technique that analyses microstructural white matter integrity by measuring diffusivity in different directions: axial diffusivity correlates with axonal injury, radial diffusivity with myelin breakdown, and fractional anisotropy is a composite measure that represents general white matter integrity.
FTLD-associated gene, identified in 2015 5 . Although some phenotypes are associated with specific mutations -for example the co-occurrence of MND with C9orf72 mutations -genotype-phenotype correlations are generally poor, even within families 3 . Sensitive biomarkers for FTD are crucial owing to the heterogeneity of the disorder. Great efforts to identify these biomarkers have been made over the past two decades, with a predominant focus on fluid bio material and neuroimaging features. According to previous consensus, the ideal biomarker should detect a fundamental pathological feature of the disease, should be validated in pathological proven cohorts, and should be precise, reliable, inexpensive and detectable through a pro cedure that is noninvasive and simple to perform 6
. Different biomarkers can be used for specific purposes, so the value of a biomarker depends on its application. In FTD, diagnostic biomarkers should discriminate between individuals with FTD, control individuals and individuals with other neurodegenerative diseases, or should differentiate between clinical, genetic or pathological subtypes. Staging biomarkers should enable us to assess disease severity and to discriminate between presymptomatic, prodromal, and early or late symptomatic stages of the disease. Pharmacodynamic biomarkers are important for the evaluation of the biological and clinical effect of future therapeutic interventions. Prediction of the underlying pathology in FTD (tau versus TDP-43) is one of the greatest challenges, as this distinction will be essential when specific disease-modifying interventions become available. Ideally, these interventions should be applied at an early stage in the disease when only minimal neuronal damage is present, which highlights the need for early biomarkers; at-risk individuals from families with genetic forms of FTD are the ideal study population for detecting these earliest changes.
In this Review, we focus on fluid and neuroimaging biomarkers in FTD. We discuss previous studies on biomarkers with their current application in clinical practice and we highlight the development of new, promising biomarkers.
Neuroimaging biomarkers
Most FTD imaging studies have focused on structural changes by assessing grey matter atrophy, but studies within the past 5-10 years have examined white matter integrity using diffusion tensor imaging (DTI); these white matter changes are probably more sensitive for the earliest changes in FTD than are grey matter changes. In neurodegenerative diseases, structural abnormalities are often preceded by functional changes; in the following sections we describe both the structural and functional changes identified with different imaging modalities. Most imaging studies have focused on group analyses, but these group-based results cannot always be translated to the individual patient, as a strong discriminative power between patient groups or outcomes is needed to apply these biomarkers in clinical practice.
Structural changes
Grey matter. The majority of imaging studies in FTD have used volumetric T1-weighted MRI to investigate changes in grey matter structure [7] [8] [9] [10] . This technique is used to measure brain volume, the rate of brain atrophy, and the volumes of specific brain regions of interest -for example, the frontal lobe or hippocampus. Several postprocessing analytical techniques have also been applied to T1-weighted imaging; for example, investigation of changes at the voxel level (such as voxel-based morphometry) or measurement of cortical thickness (using software such as FreeSurfer), each of which provide an alternative way to investigate grey matter loss in the brain.
On an individual patient level, semiquantitative assessment of atrophy using visual rating scales, performed by experienced dementia experts, has provided good diagnostic performance in the discrimination of FTD from AD (with more posterior cortical involvement seen in the latter than the former), with a specificity of 81% 11 . Clinical, genetic and pathological syndromes of FTD can also be distinguished to some degree by distinct and dissociable patterns of grey matter atrophy at a group level (FIG. 2) . Clinically, bvFTD is associated with atrophy in the frontal and temporal lobes, the insula and the anterior cingulate cortex, with the earliest involvement of frontal paralimbic cortices and insula [12] [13] [14] . Cluster analyses suggest that four anatomical forms of bvFTD exist: frontal-dominant, temporal-dominant, frontotemporal and distributed frontotemporoparietal 15, 16 . However, these analyses have underplayed the involvement of sub cortical structures in bvFTD: atrophy of the hippocampus, amygdala, basal ganglia and thalamus clearly occur as the disease progresses 14, 17 . Inthe PPA syndromes, svPPA is associated with asymmetrical (commonly leftsided) anteroinferior temporal lobe atrophy, nfvPPA with predominantly left-sided inferior frontal and insula involvement, and lvPPA with left temporo parietal junction loss 18, 19 . In each of the PPA syndromes, the extent of atrophy progresses over time, not only within the same hemisphere but also -later in the disease course -in the opposite hemisphere [20] [21] [22] . In the genetic forms of FTD, GRN mutations are associated with asymmetrical frontotemporoparietal atrophy, MAPT mutations are associated with relatively symmetrical involvement of 16, [23] [24] [25] [26] . Despite the presence of group-level patterns, identification of individuals with specific pathological forms of FTD has proved difficult when structural T1-weighted imaging is used alone, and the distinction between patients with FTLD-TDP or FTLD-tau has not been possible 9 . Patients with FTLD-FUS pathology generally present with prominent caudate atrophy, accompanied by orbitofrontal, anteromedial temporal, anterior cingulate, and insula atrophy 27, 28 . Across clinical, genetic and pathological forms of FTD, less research has been conducted to assess longitudinal changes in grey matter loss than loss at single time points. However, rates of atrophy clearly vary between different groups, with some being relatively fast (for example, in patients with GRN mutations), and some very slow (for example, a subgroup of patients with C9orf72 repeat expansions) 29 . If longitudinal structural imaging could be used for monitoring in clinical trials, sample size estimations show that focal atrophy rates, such as in the temporal lobe in svPPA, would enable use of a smaller sample than do whole brain atrophy rates 7 
.
Findings from several small studies of individuals who are at risk of genetic FTD have been inconsistent, with some showing grey matter atrophy before onset of symptoms and others not. However, in 2015, a large multi centre analysis from the Genetic Frontotemporal Dementia Initiative (GENFI) study identified the presence of atrophy in individuals with FTD-associated mutations at least 10 years before expected symptom onset (FIG. 3a) , with different genetic groups showing different patterns 30 . In individuals with MAPT mutations, atrophy was first noted in the hippocampus and amygdala, followed by the temporal lobe and later the insula; in GRN mutation carriers, differences started in the insula, followed by the temporal and parietal lobes and thereafter the striatum; in the C9orf72 group, changes were found very early (25 years before expected onset) in subcortical areas (including the thalamus), the insula and the occipital cortex, then the frontal and temporal lobes and subsequently the cerebellum 30 . In individuals with GRN mutations, but not in the other genetic subgroups, prominent asymmetry was found in the atrophy at 5 years before expected symptom onset. Examination of changes in this cohort over time is important, as small-scale longitudinal studies have proven more sensitive than cross-sectional studies, as illustrated by the identification of a significant reduction in left temporal cortical thickness over time in presymptomatic GRN carriers, with no differences found between presymptomatic individuals and noncarriers at baseline 31 
White matter. DTI is a valuable noninvasive imaging technique for the assessment of the white matter structure of the brain. This technique measures the microstructural integrity of white matter by determining the rate of diffusion (that is, the motion of water molecules) in different directions. Changes in different DTI metrics are thought to reflect different pathological changes in microstructure: a decrease in axial diffusivity correlates with axonal degeneration; an increase in radial diffusivity indicates myelin breakdown; and a decrease in fractional anisotropy -a composite measure of both axial diffusivity and radial diffusivity -represents a general, nonspecific loss of white matter integrity 32 . Abnormalities in white matter diffusivity have been found to precede grey matter atrophy in FTD and to have a more widespread distribution in the brain, supporting the importance of white matter involvement in FTD [33] [34] [35] [36] [37] [38] . DTI findings could become valuable biomarkers, as the approach has at least four potential applications: differentiation between individuals with FTD, individuals with other types of dementia, and individuals without dementia; differentiation between subtypes of FTD; disease monitoring; and detection of early changes before disease onset. However, white matter integrity has only been investigated with DTI at a group level and not at a single-patient level.
DTI enables highly sensitive differentiation between individuals with FTD, individuals with other types of dementia (such as AD) and controls without dementia [32] [33] [34] [35] [36] [38] [39] [40] [41] [42] [43] [44] [45] . Evidence has shown that changes in white matter microstructure are more widespread in people with FTD than in those with AD 32, 34, 39, 40 , and wholebrain mean fractional anisotropy enables discrimination between these conditions with a high sensitivity (78%) and moderate specificity (68%) 34 . White matter degradation co-occurs with frontal, temporal and insular atrophy in FTD, and probably results from axonal degeneration associated with grey matter neuronal loss. This degeneration encompasses the anterior corpus callosum, bilateral anterior and descending cingulum, and uncinate fasciculus tracts 42 , which are part of motor, executive and language neural networks.
Although patterns of white matter damage on DTI largely overlap between subtypes of FTD, some distinctive DTI changes have been found in clinical, pathologi cal and genetic subtypes 33, 35, 36, 38, 40, [42] [43] [44] 46 . The uncinate fasciculus, cingulum bundle and genu of the corpus callosum seem to be key tracts involved in the bvFTD disease process 34, 41, 44 . Different spatial patterns of white matter damage have been found in PPA subtypes: patients with nfvPPA show damage to the left orbitofrontal and anterior temporal white matter (superior longitudinal fasciculus); patients with svPPA show asymmetric (mostly left-sided) changes in the anterior and inferior temporal white matter (including the inferior longitudinal fasciculus), and bilateral uncinate fasciculi; and patients with lvPPA show posterior abnormalities, such as in the posterior region of the left inferior longitudinal fasciculus 33, 35, 36, 38, [42] [43] [44] . DTI might be able to differentiate FTLD-tau from FTLD-TDP in vivo: two studies have found more severe loss of white matter integrity in FTLD-tau than in FTLD-TDP 33, 46 . This observation parallels post-mortem findings in which tau pathology is associated with marked axonal loss and glial tau inclusions, and TDP-43 pathology is associated with greater grey matter neuronal loss than white matter pathology 46 . Larger studies are needed to enable conclusive observations to be made before this technique can be used to differentiate pathological subtypes in individual patients. DTI studies have revealed different patterns of white matter loss across patients with different genetic subtypes of FTD: patients with MAPT mutations have consistent alterations in the uncinate fasciculus and right parahippocampal cingulum 34, 41 , whereas patients with C9orf72-FTD tend to have a greater amount of dorsal white matter tract pathology located in the cingulum, corpus callosum and the superior cerebellar peduncles 34, 41 . Longitudinal assessment of white matter changes with DTI could also be used to monitor the disease process and evaluate therapeutic effects in future clinical trials in FTD, although studies so far are limited 41 . Over time, white matter changes have been found to be more widespread than the changes in grey matter atrophy, and have shown distinct patterns between clinical and genetic FTD subtypes, which reflect different propagation of the neurodegenerative process within large-scale brain networks 35 . In bvFTD, the largest reduction in fractional anisotropy has been seen in the bilateral uncinate fasciculus and paracallosal cingulum 35, 41 , whereas left-to-right sided progression is detected in both svPPA and nfvPPA 35, 43 . In svPPA, longitudinal white matter changes extend to bilateral frontotemporal tracts, whereas changes in nfvPPA seem to remain comparatively focal 35, 43 . Finally, the use of white matter pathology detected by DTI as a biomarker might even enable the detection of pathological changes before the onset of clinical symptoms and before grey matter atrophy in FTD. Decreased fractional anisotropy and increased radial diffusivity have been found in the bilateral uncinate fasciculi in a group of presymptomatic carriers of MAPT or GRN mutations who did not have grey matter atrophy 37, 47 (FIG. 3b) . In conclusion, white matter changes detected with DTI are a promising biomarker for early diagnosis of FTD and for monitoring the effect of pharmacological interventions in the future. For DTI to be used in individual patients, reference data are essential to enable identification of abnormal changes in white matter integrity, as in automated quantitative MRI 48 . However, the assembly of such normative data is challenging, owing to variability across scanners and field strengths, and choices of DTI metric, tract to assess, and method of analysis (for example, tracking or skeletonized analysis). Region of interest analyses of specific tracts, such as the uncinate fasciculus, inferior longitudinal fasciculus and superior longitudinal fasciculus, will probably provide the best opportunity to move forward from the current group-level studies to single-patient analyses.
Functional changes FDG-PET.
The use of PET with 18 F-fluorodeoxyglucose as the tracer (FDG-PET) enables visualization of alterations in brain metabolism that precede grey matter atrophy in FTD and different forms of dementia [49] [50] [51] [52] . Distinct patterns of regional hypometabolism detected with FDG-PET enables an accurate clinical diagnosis to be made at an individual patient level, both by visual inspection and especially by quantitative assessment 53 . Low glucose metabolism (often asymmetrical) in the orbitofrontal cortex, dorsolateral cortex, medial prefrontal cortex, anterior temporal poles, and basal ganglia, is highly specific for bvFTD, and differentiates patients with bvFTD from those with other dementia types and healthy controls with a sensitivity and specificity of 80-95% 50, 51, [53] [54] [55] [56] . These patterns of hypometabolism are early features of symptomatic bvFTD, but also occur a few years before patients fulfil the criteria for probable bvFTD 50 . However, FDG-PET has produced false positive findings in some primary psychiatric disorders that mimic FTD, so future quantitative assessment of metabolism patterns with PET are needed to increase the diagnostic value of the technique 54 . The patterns of focal hypometabolism vary between subtypes of PPA and between different genetic forms of FTD, and mirror those of the structural changes described in the previous section. svPPA is characteristically associated with asymmetrical bilateral temporal hypometabolism, whereas nfvPPA is associated with a higher variability in hypometabolic patterns of the left inferior frontal gyrus, dorsolateral frontal cortex, anterior cingulate cortex, insula, and -occasionally -the parietal cortex 57 . Distinct patterns of metabolic abnormalities in PPAs might predict progression to specific dementia subtypes: evidence suggests that bilateral temporoparietal hypometabolism predicts conversion to AD, parietal hypometabolism predicts conversion to corticobasal syndrome, and involvement of the basal ganglia, midbrain and cerebellum predicts conversion to PSP 57 . Longitudinal changes of metabolism detected by FDG-PET could provide additional information about the patterns and speed of pathological spread 31, 56 . For example, patients with svPPA exhibit a bilateral reduction of glucose metabolism in the temporal lobes over time, which extends to the anterior cingulate cortex and the posterior temporal lobes 58 . Regarding genetic subtypes, GRN mutations are associated with asymmetrical hypometabolism in frontal and temporal brain regions 31, 59 , ALS and/or FTD resulting from C9orf72 expansions is associated with hypometabolism in the limbic system, basal ganglia and thalamus 60 , and MAPT mutations are associated with hypometabolism in the medial temporal lobe and the frontal and parietal cortices 24 . Interestingly, FDG-PET can reveal abnormalities in the presymptomatic stage of FTD, and could serve as a surrogate endpoint in future therapeutic trials; asymmetrical hypometabolism was found in the frontal and temporal lobes of asymptomatic GRN carriers before the onset of clinical symptoms and of grey matter atrophy 31, 59 .
Arterial spin labelling. The MRI technique arterial spin labelling (ASL) measures brain perfusion noninvasively by magnetically labelling water protons in arterial blood, which creates an endogenous tracer of cerebral blood flow 61 . Brain perfusion measured by ASL correlates very well with metabolism measured by FDG-PET 51, 53 , but ASL has several advantages over FDG-PET: ASL can be combined with other MRI techniques in a single session, is noninvasive, involves no radiation exposure, is widely available and is less costly 62 . In patients with FTD, ASL has detected hypoperfusion in the insula, the amygdala and several parts of the medial frontal lobes, including the anterior cingulate 51, 53, [63] [64] [65] . ASL has also been used to differentiate bvFTD from AD at an early phase, with a diagnostic accuracy (area under the receiver operating characteristic curve) of up to 0.87 for cerebral blood flow in specific frontal or parietal regions 51, 53, 63 . In two comparative studies, the regions of hypoperfusion identified on ASL MRI scans largely overlapped with those identified on FDG-PET scans 51, 53 , and diagnostic performance for distinguishing bvFTD from AD and controls was similar for both modalities 53 . Brain perfusion measured by ASL could also be an early biomarker in the preclinical stage of genetic FTD. Decreases in cerebral blood flow over time are significantly larger in presymptomatic individuals who carry GRN or MAPT mutations than in control individuals (FIG. 3c) , independent of grey matter atrophy, in widespread frontal, temporal, parietal, and subcortical regions; the largest decline in perfusion was observed in those who converted to the disease stage 62 . Some regional changes in brain perfusion might be specific for particular gene defects, as hypoperfusion can extend into posterior temporal and parietal regions in those with a GRN mutation 62 . Resting-state functional MRI. Another potential biomarker for early diagnosis and disease staging in FTD is functional connectivity measured with resting-state functional MRI (RS-fMRI). RS-fMRI measures intrinsic functional connectivity between brain regions, which can be detected as synchronous patterns of spontaneous, low-frequency fluctuations in blood oxygen leveldependent signals. RS-fMRI is a safe, noninvasive and repeatable tool that is sensitive to changes in brain functional connectivity before the onset of clinical symptoms or atrophy at the group level, as opposed to the individual level 37, 66, 67 . Decreased connectivity between the frontoinsula and anterior cingulate cortex, part of the salience network, is the most consistent RS-fMRI finding in patients with FTD [67] [68] [69] [70] [71] , but some studies have found normal or increased connectivity [72] [73] [74] . Inconsistent differences (increased and decreased connectivity) have been found in the default mode network in FTD [67] [68] [69] . These discrepancies in functional connectivity might partly be explained by differences between cohorts and scanners, and by the wide variation in analytical methods used, such as independent component analyses, seed-based or region-of-interest-based approaches, or regional homogeneity analyses 66, 68, 72, 74, 75 . Specific network alterations are also found in different clinical and genetic subtypes of FTD. Reduced left temporal lobe connectivity is found in svPPA 76, 77 , attenuated connectivity in salience and sensorimotor networks is found in patients with C9orf72 bvFTD 26 , and reduced left frontal connectivity is found in patients with GRN mutations 78 . In the presymptomatic phase of FTD, RS-fMRI might be sensitive to connectivity differences: altered (reduced and increased) frontoinsula and/or anterior cingulate cortex connectivity have been reported in presymptomatic mutation carriers 37, 66, 78, 79 .
Amyloid and tau PET tracers. Several tracers other than
18 F-fluorodeoxyglucose could be used to identify diagnostic biomarkers in the differential diagnosis between FTD and AD, and between different pathological subtypes of FTD. PET with an amyloid tracer, such as Pittsburgh compound B (PiB), robustly and sensitively detects amyloid-β deposits, which indicate AD pathology in vivo 80 , whereas bvFTD, svPPA and nfvPPA are mostly PiB-negative. Most lvPPA cases are atypical AD cases and are associated with a PiB binding pattern similar to that seen in AD [81] [82] [83] , but lvPPA with negative PiB-PET is accompanied by structural and FDG-PET abnormalities, which support an underlying FTLD pathology 83, 84 . Unexpected positive PiB-PET findings in patients with FTD can result from mild coincidental AD pathology, unrelated to the clinical FTD presentation 85 . Several tracers have been developed that visualize tau pathology in vivo; however, an ideal ligand that captures the wide range of tau pathology in existence has not yet been developed. Selectivity to different tau isoforms and their intracellular aggregation probably requires the application of different tau ligands 86 . In tau PET with the 18 F-AV-1451 ligand (also known as flortaucipir), increased uptake in the temporal cortex, frontal cortex, and basal ganglia is seen in patients with FTD who have an Arg406Trp MAPT mutation, which is associated with both 3-repeat and 4-repeat tau pathology. In these patients, increased regional 18 F-AV-1451 uptake correlated with decreased glucose metabolism and with the post-mortem burden of tau pathology 87 . However, conditions in which only 4-repeat tau pathology is present are associated with poor binding of 18 F-AV-1451, as illustrated by the lack of correlation between 18 F-AV-1451 binding and post-mortem tau pathology in PSP 88, 89 . A 2017 study of post-mortem brains reported that the ligand 11 C-PBB3 could more Nature Reviews | Neurology robustly capture a wide range of tau pathologies than 18 F-AV-1451, including 3-repeat and 4-repeat tau conditions 90 . Furthermore, the 18 F-THK-5351 ligand produced promising results in the 4-repeat tau diseases PSP and cortico basal syndrome, in post-mortem tissue and in vivo 91, 92 . Once validated, tau PET could become effective for the diagnosis of underlying tau pathology in FTD and could provide a surrogate marker for trials with anti-tau therapeutics 86 .
Summary of imaging biomarkers
Grey matter atrophy and hypometabolism are validated diagnostic biomarkers that show fairly consistent changes between studies at a group level, and are clinically applied at an individual level for the differentiation between FTD, AD and control individuals (TABLE 1) . More work is required on the use of imaging modalities to distinguish FTD subtypes at an individual level, with a need for larger studies of longitudinally acquired imaging data, before these techniques can be used as an outcome measure to monitor disease progression in clinical trials.
We expect that new modalities, such as DTI, ASL and RS-fMRI, will become valuable tools for detecting biomarkers in clinical practice, especially owing to their sensitivity, and have the potential to enable early diagnosis and longitudinal monitoring of disease (TABLE 1) . Crucial to the implementation of these techniques is the harmonization of methodology across different centres, as scanners and protocols can vary considerably. For example, the diversity of ASL scanning protocols influences perfusion quantification, which could be overcome by a proposed international standardization of protocols 61 . Additionally, the integration of different types of information through the combination of imaging modalities holds great promise for the future, as demonstrated by multimodal analyses that have improved the discrimination between FTD and AD 40, 45, 52, 65, 93, 94 , and between clinical FTD subtypes 94 .
Fluid biomarkers
Alterations in the concentrations of specific proteins in different human fluid compartments could reflect pathophysiological changes in disease processes. The 
Single molecule array technology
A digital form of enzyme-linked immunosorbent assay that runs highly sensitive immunoassays to measure molecules (for example proteins) in biofluids.
proximity of cerebrospinal fluid (CSF) to the brain means that it is likely to contain disease-specific biomarkers in patients with neurological disease. Subsequent validation of such biomarkers in blood would be of great value, as the acquisition of blood samples is minimally invasive and would enable repeated measurements to be taken over time. Some brain-specific proteins in neurodegenerative disorders can be detected reliably in blood by novel ultrasensitive assays -such as single molecule array technology. In the next few years, the progress resulting from these developments will offer new opportunities for the diagnosis, staging and monitoring of patients with FTD. In this section, we will first review the current CSF markers used to differentiate FTD from AD, then highlight promising CSF and blood-derived biomarkers in sporadic and genetic FTD.
CSF amyloid-β and tau
The core CSF biomarkers for AD are phospho-tau 181 (p-tau), total-tau (t-tau), and amyloid-β 1-42 (Aβ 1-42 ); these species correspond to the pathological changes that occur in AD -that is, accumulation of hyperphosphorylated tau in neurofibrillary tangles, neuronal loss (associated with increased CSF levels of t-tau), and Aβ deposition in senile plaques, respectively 95 . These biomarkers have been comprehensively validated to exclude AD in the diagnostic work-up of FTD, both in clinical cohorts and in small, pathologically confirmed case series: higher levels of p-tau and t-tau, and lower levels of Aβ are found in patients with AD than in those with FTD 96 . A high ratio of p-tau:Aβ 1-42 or t-tau:Aβ 1-42 enables an especially accurate diagnostic performance for the differentiation of FTD from AD (p-tau:Aβ 1-42 -specificity 80% and sensitivity 87%; t-tau:Aβ 1-42 -specificity 79% and sensitivity 89%). The use of ratios of other Aβ isoforms could improve diagnostic accuracy, especially when differentiating between AD and vascular dementia or dementia with Lewy bodies, but also for distinguishing AD from FTD 97, 98 . The core AD biomarkers are also valuable for differentiating between underlying AD or FTLD pathology in the differential diagnosis of PPA, in which an AD-like CSF profile is often found in patients with clinically diagnosed lvPPA, but not in patients with svPPA or nfvPPA [99] [100] [101] [102] . An AD-like CSF profile occasionally occurs in patients with FTD, even in pathologically proven cases, which could partly be explained by the co-occurrence of AD pathology with FTLD in these patients 103 . Moreover, decreased Aβ 1-42 levels (compared with reference ranges) were found in up to 25% of patients with the C9orf72 repeat expansion in a Finnish cohort, but not in patients with a GRN mutation; additional clinicopathological and genetic studies are required to elucidate the pathophysiological relevance of Aβ 1-42 in these cases [104] [105] [106] . F-fluorodeoxyglucose PET; FTD, frontotemporal dementia; NfL, neurofilament light chain; NS, not studied; poly(GP), glycine-proline repeating protein; p-tau, phospho-tau 181 ; RS-fMRI, resting-state functional MRI; tau-PET, tau PET; t-tau, total-tau.
CSF levels of tau are not increased in patients with FTD with underlying tau pathology or in patients with MAPT mutations, compared with patients with taunegative or sporadic FTD 107, 108 . The ratio of p-tau:t-tau is lower in FTLD-TDP than in FTLD-tau, and enables a specific differentiation between these subtypes; however, this relationship seems to be driven by the presence of concomitant MND in some individuals with FTLD-TDP [109] [110] [111] [112] . Whether the lower ratio of p-tau to t-tau is the result of an increase in t-tau owing to neuronal loss or a reduction of p-tau is not completely clear. Interestingly, in line with the hypothesis of neuronal damage, one study found an association between reduced p-tau:t-tau ratio and survival in patients with FTD 111 .
Neurofilament proteins
Neurofilament light chain (NfL) probably has the most promising short-term prospects of all fluid biomarkers for FTD disease monitoring and prognosis.
Neurofilaments are the major constituent of the neuroaxonal cytoskeleton and play an important part in axonal transport and in the synapse 113 . NfL is the most abundant and soluble neurofilament subunit, and increased levels are thought to reflect axonal damage.
Blood and CSF levels of NfL are 2.5-11-fold higher in patients with FTD than in control individuals, and the clinical value of this protein lies in its correlation with disease severity and progression, survival, and cere bral atrophy 111, [114] [115] [116] [117] [118] [119] (FIG. 4) . CSF NfL is also increased, although to a lesser extent, in several other neurodegenerative diseases (such as ALS, AD, PSP and vascular dementia), and should, therefore, be combined with disease-specific biomarkers 114, 117, [120] [121] [122] . Levels of NfL are equally elevated among the FTD subtypes bvFTD, nfvPPA and svPPA, and are strongly increased in FTD with MND 111, [114] [115] [116] 118 . High CSF levels of NfL were found in patients with TDP-43 pathology compared with tau pathology, a difference that was largely Nature Reviews | Neurology driven by ALS co-occurrence 111, 118 . Among the genetic subgroups, particularly high NfL levels were found in FTD patients with GRN mutations, levels varied greatly in patients with C9orf72 expansions (ranging from high levels in concomitant MND to low levels in patients who progress slowly), and patients with MAPT mutations had comparatively low levels 115 (FIG. 4b) . Interestingly, presymptomatic individuals with FTD-associated mutations have normal levels of NfL in CSF and blood, with a sharp increase reported after conversion to the disease stage in two individuals 115 (FIG. 4b) .
Whether and in what manner NfL levels fluctuate over time in FTD is unknown, but longitudinal data in ALS have shown stable NfL levels or a minor increase over time 120, 123 . A strong correlation has been shown between NfL levels in CSF and serum, which makes this biomarker measurable in blood and, therefore, especially suitable for repeated measurements 115, 119 . In mouse models of neurodegenerative diseases that exhibited tau, Aβ or α-synuclein pathology, an increase in blood and CSF levels of NfL coincided with the onset and progression of brain pathology; inhibition of Aβ production -thus, reducing Aβ lesions -attenuated the NfL increase 124 . This observation suggests that we can use NfL to monitor treatment response in neurodegenerative diseases. In conclusion, NfL is a promising, noninvasive biomarker for disease staging, monitoring and prognosis in FTD. Longitudinal studies in FTD need to be conducted to better understand the role of NfL as a marker of disease progression.
Gene-specific biomarkers
Progranulin. The multifunctional protein progranulin plays an important part in neurite outgrowth and inflammation 125 . Pathogenic loss-of-function mutations in GRN reduce the blood and CSF levels of progranulin to 25-40% of normal levels, owing to haploinsufficiency [125] [126] [127] [128] [129] . Blood or CSF levels of progranulin are diagnostic biomarkers of pathogenic GRN mutations, as they enable the discrimination of presymptomatic and symptomatic GRN mutation carriers from noncarriers with high sensitivity (96-100%) and specificity (93-100%) 128, 129 (FIG. 5a) . Consequently, blood levels of progranulin can help to assess the pathogenicity of unclassified variants in GRN. Currently, therapeutic trials are focusing on interventions that increase progranulin expression, such as histone deacetylase inhibitors 130 . In these trials, target engagement is assessed using blood progranulin levels, as they seem to be constant over time 129, 131 . However, blood and CSF levels of progranulin are differentially regulated, as demonstrated by the moderate correlation between these compartments in GRN mutation carriers; therefore, CSF should also be sampled 129 . Progranulin levels thus provide a good pharmacodynamic biomarker, but do not reflect the extent of neurodegeneration in the brain, for which additional biomarkers are needed as surrogate endpoints.
Dipeptide-repeat proteins translated from the C9orf72 repeat expansion. C9orf72 repeat expansions are transcribed to G 4 C 2 repeat RNA, which forms RNA foci. Nature Reviews | Neurology In parallel, this RNA is translated into proteins of repeating dipeptides (dipeptide-repeat (DPR) proteins) by repeat-associated nonATG-initiated translation 132 . RNA foci and DPRs are both thought to have a key role in the pathophysiology resulting from the G 4 C 2 expansion [132] [133] [134] . Elevated levels of glycine-proline-repeating protein (poly(GP)), one of the DPR proteins, have been found in the CSF of patients with C9orf72 repeat expansions, and also in presymptomatic carriers of the expansion 134, 135 ( FIG. 5b) . Moreover, poly(GP) levels remained fairly constant over time, which supports the use of poly(GP) as a potential pharmacodynamic biomarker in future therapeutic trials 135 . In human cell models of C9orf72 FTD-ALS, antisense oligonucleotides that bind to G 4 C 2 RNA reduce the levels of extracellular poly(GP), and in mice harbouring a G 4 C 2 expansion, they reduce the number of RNA foci and total levels of DPR proteins, as well as CSF levels of poly(GP) [133] [134] [135] . These findings indicate that poly(GP) is a potential biomarker for therapeutic target engagement and enables the measurement of biochemical responses to treatment with agents such as antisense oligonucleotides 134, 135 . As CSF levels of poly(GP) did not correlate with age at onset, disease duration, symptom severity or survival in patients with C9orf72 repeat expansions, future clinical trials in these patients could benefit from the combination of poly(GP) levels as a pharmacodynamic marker and NfL levels as a prognostic marker.
Potential fluid biomarkers
As FTLD with phosphorylated TDP-43 (pTDP-43) aggregates constitutes one of the major pathological subgroups of FTLD, levels of pTDP-43 protein in CSF or blood would be an interesting biomarker. However, to date, results have been contradictory. Strongly elevated CSF levels of pTDP-43 have been found in a small series of patients with C9orf72 or GRN mutations, but did not differ between FTD with TDP-43 or tau pathology in a pathology-proven cohort 112, 136 . Quantifi cation of levels of pTDP-43 in CSF is challenging owing to low concentrations, the presence of different isoforms, and various antibodies that recognize different regions of pTDP-43 and vary in specificity 112, 137 ; the development of better TDP-43 assays is warranted.
Neuroinflammation plays an important part in FTD and other neurodegenerative diseases, as it is a consequence and a trigger of pathology 138 . Microglia are the major immune component of the CNS, and are activated by damaged neurons and misfolded proteins, resulting in the initiation of a chronic inflammatory response 138 . A study of patients with sporadic FTD or AD found reduced levels of soluble triggering receptor expressed on myeloid cells 2 (TREM2), a protein involved in inflammation and phagocytosis and mainly expressed by microglia 139 . CSF levels of chitinase-3-like protein 1 (also known as YKL-40 or cartilage glycoprotein-39), an inflammatory protein produced by astrocytes, were found to be elevated in pathologically proven FTD, but also in AD, vascular dementia, normal ageing and other neurological disorders, such as multiple sclerosis [140] [141] [142] . Similarly, glial fibrillary acidic protein, an astrocytic cytoskeletal protein, was found to be increased in FTD and other dementia types 143 . In the past few years, a strong link between GRN mutations and microglial activation has been established, with excessive complement production leading to synaptic pruning 144 . Promisingly, data suggest that proteins involved in complement activation are potential biomarkers of disease progression in GRN mutation carriers 144 . Various changes in CSF and/or blood levels of cytokines (primarily pro-inflammatory cytokines, such as MCP-1, IL-6 and TNF) have been found in FTD, but these changes seem to reflect nonspecific mechanisms, as they are also present in AD [145] [146] [147] [148] [149] [150] . The role of several neuropeptides in FTD has been extensively reviewed elsewhere 151 ; for example, levels of neurogranin, a postsynaptic protein involved in synaptic plasticity, were lower in patients with FTD than in control individuals and patients with AD 141 . Larger cohorts with pathologically proven and genetically determined disease are needed for validation of these cytokines and neuropeptides.
Novel approaches are focusing on enriched protein fractions and microRNAs in exosomes as potential biomarkers. Exosomes are vesicles secreted from cells; they facilitate intercellular communication and are enriched sources of biomolecules. The value of the examination of exosomes is supported by a small study that reported reduced levels of synaptic proteins in blood-derived exosomes in FTD 152 . microRNAs regulate gene expression, and seem to have a role in TDP-43 and FUS pathology, but have not yet been reported as biomarkers in FTD 153 .
Summary of fluid biomarkers
Several fluid biomarkers for FTD are currently usable (for example, core AD biomarkers such as tau and Aβ levels) or show promise (for example, levels of NfL) (TABLE 1) . Combinations of metabolites in the CSF are likely to yield more information than single markers; for example, one biomarker panel enabled highly sensitive differentiation between TDP-43 pathology and tau pathology 145 . Generally, more validation and longitudinal data are needed to determine the full potential of fluid biomarker candidates. Lastly, harmonization of fluid biomarker collection and analysis is important, as levels of the markers can be influenced by multiple pre-analytical and analytical factors, including sampling and storage methods, and choice and implementation of assays 154 . Multicentre standardization of these procedures and the establishment of quality control programmes will facilitate collaborative research and the implementation of new fluid biomarkers in clinical practice.
Conclusions
Neuroimaging and fluid biomarkers are becoming increasingly important in the context of future therapeutic interventions in sporadic and genetic forms of FTD. Several imaging and CSF biomarkers (such as grey matter atrophy, FDG-PET findings and CSF biomarkers of AD) are already established and being used in clinical practice, often in the differential diagnosis of FTD versus AD. Progress is being made in the identification of gene-specific markers and the discovery of new biomarkers for disease staging, the prediction of underlying pathology and monitoring of treatment responses. For example, DTI has performed well in discriminating between FTD and AD, and in demonstrating early pathological changes; NfL can be used to differentiate patients with FTD from control individuals and is a promising staging and prognostic biomarker for FTD; and genetic-specific biomarkers (such as progranulin and DPR proteins) could be valuable for the assessment of target engagement in therapeutic trials. Importantly, combinations of biomarkers will be valuable in enabling the accurate definition of FTD subtype and disease onset, and for the monitoring of disease progression and, eventually, treatment response. For example, in a trial in which the aim is to increase progranulin production, target engagement could be assessed by progranulin levels, but additional surrogate endpoints would be needed to assess the physiological effect (that is, the reduction of neurodegeneration).
Most alterations of these novel biomarkers have been demonstrated at a group level and need to be validated for individual patients, which is challenging because FTD is fairly rare. Multicentre research can help to increase statistical power and prove clinical utility; prime examples of longitudinal observational cohorts include GENFI, ARTFL (Advancing Research and Treatment for Frontotemporal Lobar Degeneration Consortium), LEFFTDS (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects), and a collaboration including these consortia in the FPI (FTD Prevention Initiative). Research in genetic FTD provides a unique opportunity to study the earliest disease effects and consequently offers good prospects for the identification of valuable biomarkers. Despite similarities between genetic and sporadic FTD, biomarkers identified in genetic cases require validation for use in sporadic cohorts, as biomarker profiles and trajectories can differ, as they do in AD 155 . Interestingly, researchers are now emphasizing that FTD, which has typically been considered an early-onset dementia, frequently manifests after the age of 65 years and can include clinical features suggestive of AD 156, 157 . This finding stresses the need for diagnostic biomarkers that are specific for FTD, as the co-occurrence of AD pathology with FTD increases with age. The value of FTD biomarkers in different age groups with comorbidities remains to be elucidated. Additionally, future research should focus on the combination of different biomarkers (both fluid and ima ging) to make optimal use of these modalities, as well as on harmonization of collection and analysis protocols to facilitate dissemination in research and clinical practices.
